Review Article, J Immunodefic Disor Vol: 3 Issue: 1
Alpha-Fetoprotein as a Biomarker in Immunodeficiency Diseases: Relevance to Ataxia Telangiectasia and Related Disorders, Immunodiagnostics
| Gerald J Mizejewski* | |
| Wadsworth Center, Division of Translational Medicine, New York State Department of Health, The Empire State Plaza, Albany, NY 12209, USA | |
| Corresponding author : Gerald J Mizejewski Wadsworth Center, New York State Department of Health, The Empire State Plaza, PO Box 509 Tel: 518 486-5900; Fax: 518 402-5002 E-mail: mizejew@wadsworth.org |
|
| Received: October 30, 2013 Accepted: March 17, 2014 Published: March 24, 2013 | |
| Citation: Mizejewski GJ(2014) Alpha-Fetoprotein as a Biomarker in Immunodeficiency Diseases: Relevance to Ataxia Telangiectasia and Related Disorders. J Immunodefic Disor 3:1. doi:10.4172/2324-853X.1000108 |
Abstract
Alpha-Fetoprotein as a Biomarker in Immunodeficiency Diseases: Relevance to Ataxia Telangiectasia and Related Disorders
Human Alpha-fetoprotein (AFP) involvement as a biomarker in immunodeficiency disorders (IDD) has received little attention in the biomedical literature due to the recent focus on AFP epitope analysis, vaccine development, and regulation of T- and B-cell immune responses. Thus, the literature is currently devoid of a review which encompasses the use of AFP as a biomarker in the different types of IDDs. In order to update and increase present knowledge regarding an AFP-IDD relationship, the present review surveys and addresses the presence of AFP serum levels in patients with IDDs such as acquired immunodeficiency syndrome (AIDS), severe combined immunodeficiency (SCID), adenosine deaminase deficiency (ADD), and in pregnant women infected with the human immunodeficiency virus (HIV).